Presentations and Publications

Reneo Pharmaceuticals Research

REN001, a novel peroxisome proliferator-activated receptor delta (PPARδ)agonist, improves gait in patients with primary mitochondrial myopathy after 12-weeks

Alcock et al., Neuromuscular Medicine, 2022

Click to view

An open-label study to evaluate the safety and tolerability of 12 weeks treatment with oral REN001 in patients with primary mitochondrial myopathy (PMM), with an optional extension of treatment

Gorman et al.,Wellcome Trust UK Mitochondrial Medicine, 2021

Click to view

Characterization of Fatigue in Primary Mitochondrial Myopathy: Findings from a Qualitative Interview Study

Karaa et al., UMDF Mitochondrial Medicine, 2021

Click to view

Development of a Patient-Reported Outcome Questionnaire for Patients with Fatty Acid Oxidation Disorders

Mathias et al., INFORM, 2019

Click to view

Peroxisome Proliferator-Activated Receptor δ Agonist, HPP593, Prevents Renal Necrosis under Chronic Ischemia

Fedorova et al., PLOS ONE 2013

Click to view